Portal de investigación
Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Martínez Valle F
- Galán Dávila L
- Buades Reinés J
- Gonzalez-Moreno J
- Losada López I
- Muñoz Beamud F
- Bárcena Llona JE
- Romero Acebal M
- Tarilonte P
- Setaro F
- Rejas-Gutierrez J
- López-Ibáñez de Aldecoa A
- Peral C
Grupos
Abstract
OBJECTIVE: Variant transthyretin (ATTRv) amyloidosis is a rare genetic multisystem disease inducing progressive morbidity. Evidence about its economic burden is scarce. This study estimated annual use and costs of healthcare-resource-utilization (HRU) and indirect costs for ATTRv mutation carriers and patients with polyneuropathy from a societal perspective in Spain. METHODS: A cross-sectional, retrospective non-interventional multicenter study was conducted in 2018-2020 to characterize asymptomatic carriers of mutations in the TTR gen (AC) and Coutinho stage 1 transthyretin amyloidosis polyneuropathy patients (PA). HRU, associated costs, and indirect wages were assessed during 12 months prior to enrollment. RESULTS: One-hundred-five participants were analyzed: 86 AC and 19 PA. Average healthcare cost-per-person-per-year was significantly higher in PA: €2,323.6 vs. €953.3 (p < 0.001), due to higher utilization of medical specialty visits, hospitalizations, and nerve conduction studies. Indirect costs were statistically not different (€380.1 for AC and €781.3 for PA, p = 0.581). Days worked with fatigue/pain were significantly higher in PA: 53.9 vs 5.5 (p = 0.034). Total cost was significantly higher in PA than AC (€3,105.0 vs €1,333.4; p < 0.001). CONCLUSIONS: Both AC and early-stage ATTRv-PN patients showed a meaningful economic burden to the National Health System and society. We observed an annual incremental economic burden of €1,771.5 in PA versus AC.
Datos de la publicación
- ISSN/ISSNe:
- 1473-7167, 1744-8379
- Tipo:
- Article
- Páginas:
- 1115-1123
- PubMed:
- 40611615
- Factor de Impacto:
- 0,552 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Expert Review of Pharmacoeconomics & Outcomes Research TAYLOR & FRANCIS LTD
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- Hereditary transthyretin amyloidosis with polyneuropathy; asymptomatic carrier; cost-of-illness; early stage; healthcare resources utilization
Cita
Martínez F,Galán L,Buades J,Gonzalez J,Losada I,SEVILLA T,Muñoz F,Bárcena JE,Romero M,Tarilonte P,Setaro F,Rejas J,López A,Peral C. Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers. Expert Rev. Pharmacoecon. Outcomes Res. 2025. 25. (7):p. 1115-1123. IF:2,200. (3).